The University of Southampton
University of Southampton Institutional Repository

Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma

Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma
Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma
The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ?3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P=<0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P<0.001). Naive CD8(+) lymphocytes (P=0.014) and transitional B cells (P=0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/auto-SCT followed by appropriate revaccination.Bone Marrow Transplantation advance online publication, 14 May 2012; doi:10.1038/bmt.2012.73.
auto-SCT, long term, immune reconstitution, immunity, lymphoma, quality of life
0268-3369
1545–1551
Dean, H.F.
ee78acf3-2344-4e21-8b34-02b2e9b18f34
Cazaly, A.
f9b61bc5-e4ec-483a-8115-eb2235b3b703
Hurlock, C.
6cfab616-4710-488e-aab9-81685c301770
Borras, J.
7dc75f77-a0fd-4566-890d-c45086f894d6
Williams, A.P.
8efc1c43-4250-47d9-ad40-640d4c147b29
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Dean, H.F.
ee78acf3-2344-4e21-8b34-02b2e9b18f34
Cazaly, A.
f9b61bc5-e4ec-483a-8115-eb2235b3b703
Hurlock, C.
6cfab616-4710-488e-aab9-81685c301770
Borras, J.
7dc75f77-a0fd-4566-890d-c45086f894d6
Williams, A.P.
8efc1c43-4250-47d9-ad40-640d4c147b29
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, A.J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Dean, H.F., Cazaly, A., Hurlock, C., Borras, J., Williams, A.P., Johnson, Peter W.M. and Davies, A.J. (2012) Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma. Bone Marrow Transplantation, 47 (12), 1545–1551. (doi:10.1038/bmt.2012.73). (PMID:22580768)

Record type: Article

Abstract

The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ?3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P=<0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P<0.001). Naive CD8(+) lymphocytes (P=0.014) and transitional B cells (P=0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/auto-SCT followed by appropriate revaccination.Bone Marrow Transplantation advance online publication, 14 May 2012; doi:10.1038/bmt.2012.73.

This record has no associated files available for download.

More information

Published date: 14 May 2012
Keywords: auto-SCT, long term, immune reconstitution, immunity, lymphoma, quality of life
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 340836
URI: http://eprints.soton.ac.uk/id/eprint/340836
ISSN: 0268-3369
PURE UUID: aa898390-127e-4175-81e0-5a5576c655ae
ORCID for Peter W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974
ORCID for A.J. Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 03 Jul 2012 15:42
Last modified: 15 Mar 2024 03:31

Export record

Altmetrics

Contributors

Author: H.F. Dean
Author: A. Cazaly
Author: C. Hurlock
Author: J. Borras
Author: A.P. Williams
Author: A.J. Davies ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×